<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20110528006617N6</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2021-07-07</date_registration>
      <primary_sponsor>Esfahan University of Medical Sciences</primary_sponsor>
      <public_title>The effect of oral zolpidem on hemodinamic indicies and the patients Equlibrium in Stereotaxic surgeries.</public_title>
      <acronym></acronym>
      <scientific_title>Survery of the effect of oral zolpidem on hemodinamic signs and the patients Equlibrium in Stereotaxic surgeries.</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2021-07-10</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>64</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/57316</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Random function "Random Number Generation " of Excel software based on patient file number will be used for randomization. Patients file number were entered into Excel program and patients were divided into case and control groups based on the random button. In total, there were two groups of 64 people. In this case, the file number is entered in Excel program, then a random number is selected from the data analysis command. This study has 2 groups that can be numbered from 1 to 2, respectively. We also want 32 people in each group. As a result, sequences 1 to 2 should be repeated 32 times each time. It is clear that the repetition of each number occurs once in each group, so select 1 for repeating each number and 32 for repeating the sequence. In this way, 64 units will be produced, Blinding description: We produced tablet  similar to Zolpidem,The once group received one tablet of Zolpidem 1 hour before surgery and the second group  received one tablet  of Placebo 1 hour before surgery. So the patients do not have any information about the intervention and the person who registered the information do not know which patient in which group ist and the study has two blind side.</study_design>
      <phase>3</phase>
      <hc_freetext>General anesthesia.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group:  Initially,personal consent is obtained from the patients.This group receive 10 mg tablet of zolpidem 1 hour before surgery,Then the patient is placed on the perating bed and standard monitoring devices including pulsoximetry,capnography are attached and Induction of anesthesia with 0/05mg/kg Midazolam, 2 microgram/Kg Fentanil . Intervention 2: Control group: Initially,personal consent is obtained from the patients.This group receive tablet of placebo 1 hour before surgery,Then the patient is placed on the perating bed and standard monitoring devices including pulsoximetry,capnography are attached and Induction of anesthesia with 0/05mg/kg Midazolam, 2 microgram/Kg Fentanil .</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is No further Information is available.</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Mehrdad Masoudifar</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Alzahra Hospital, Sofe Blvd, Shahid Keshvari highway</address>
        <city>Isfahan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>8174675731</zip>
        <telephone>+98 31 3620 2020</telephone>
        <email>masoudifar@med.mui.ac.ir</email>
        <affiliation>Esfahan University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Mehrdad Masoudifar</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Alzahra hospital, Sofe Blvd, Shahid Keshvari highway</address>
        <city>Isfahan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>8174675731</zip>
        <telephone>+98 31 3620 2020</telephone>
        <email>masoudifar@med.mui.ac.ir</email>
        <affiliation>Esfahan University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Age between 20 – 65 years old
Patients who consent to the informed consent to participate in the study
ASA class 1,2</inclusion_criteria>
      <agemin>20 years</agemin>
      <agemax>65 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Use of sedative drugs
Addiction to Alcohol
Allergic reaction to drug
Parkinsons disease
Obstructive sleep apnea
Patients who have bradycardia</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>T88.5</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Other complications of anesthesia</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Placebo</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group:  Initially,personal consent is obtained from the patients.This group receive 10 mg tablet of zolpidem 1 hour before surgery,Then the patient is placed on the perating bed and standard monitoring devices including pulsoximetry,capnography are attached and Induction of anesthesia with 0/05mg/kg Midazolam, 2 microgram/Kg Fentanil .</i_keyword>
      <i_keyword>Control group: Initially,personal consent is obtained from the patients.This group receive tablet of placebo 1 hour before surgery,Then the patient is placed on the perating bed and standard monitoring devices including pulsoximetry,capnography are attached and Induction of anesthesia with 0/05mg/kg Midazolam, 2 microgram/Kg Fentanil .</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Systolic blood pessure. Timepoint: Basic time(one hours before surgery), before anesthesia induction, 1,3,5,10,15 min after anesthesia, in the time of patient enter to the recovery and every 15 min time of patient enter to the recovery. Method of measurement: Mm-hg, sphygmomanometer.</prim_outcome>
      <prim_outcome>Diastolic blood pressure. Timepoint: Basic time(one hours before surgery), before anesthesia induction, 1,3,5,10,15 min after anesthesia, in the time of patient enter to the recovery and every 15 min time of patient enter to the recovery. Method of measurement: Mm-hg, sphygmomanometer.</prim_outcome>
      <prim_outcome>Heart rate. Timepoint: Basic time(one hours before surgery), before anesthesia induction, 1,3,5,10,15 min after anesthesia, in the time of patient enter to the recovery and every 15 min time of patient enter to the recovery. Method of measurement: ECG monitor.</prim_outcome>
      <prim_outcome>Mean arterial pressure. Timepoint: Basic time(one hours before surgery), before anesthesia induction, 1,3,5,10,15 min after anesthesia, in the time of patient enter to the recovery and every 15 min time of patient enter to the recovery. Method of measurement: Mm-hg, sphygmomanometer.</prim_outcome>
      <prim_outcome>O2 saturation. Timepoint: Basic time(one hours before surgery), before anesthesia induction, 1,3,5,10,15 min after anesthesia, in the time of patient enter to the recovery and every 15 min time of patient enter to the recovery. Method of measurement: O2 saturation percentage , pulse oximeter device.</prim_outcome>
      <prim_outcome>Surgeon Satisfaction. Timepoint: End of the surgery. Method of measurement: Likert Scale.</prim_outcome>
      <prim_outcome>Patient Satisfaction. Timepoint: End of the surgery. Method of measurement: Likert Scale.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Esfahan University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2020-10-26</approval_date>
        <contact_name>Ethics committee of Isfahan University of Medical sciences</contact_name>
        <contact_address>Isfahan University Of Medical Science, Hezar Jarib Ave Isfahan Isfehan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
